{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:34:26Z","timestamp":1770503666576,"version":"3.49.0"},"reference-count":48,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"5","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2008]]},"DOI":"10.2133\/dmpk.23.328","type":"journal-article","created":{"date-parts":[[2008,11,5]],"date-time":"2008-11-05T06:01:03Z","timestamp":1225864863000},"page":"328-339","source":"Crossref","is-referenced-by-count":11,"title":["A Novel Approach to the Prediction of Drug-Drug Interactions in Humans Based on the Serum Incubation Method"],"prefix":"10.2133","volume":"23","author":[{"given":"Yoshihiro","family":"Shibata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.23.328_bb0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/1389200003338947","article-title":"Sense and nonsense in the prediction of drug-drug interactions","volume":"1","author":"Lin","year":"2000","journal-title":"Curr. Drug Metab."},{"key":"10.2133\/dmpk.23.328_bb0010","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufactures of America (PhRMA) perspective","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2174\/1389200033489361","article-title":"Drug metabolism and drug interactions: application and clinical value of in vitro models","volume":"4","author":"Venkatakrishnan","year":"2003","journal-title":"Curr. Drug Metab."},{"key":"10.2133\/dmpk.23.328_bb0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/1389200043489072","article-title":"Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration","volume":"5","author":"Blanchard","year":"2004","journal-title":"Curr. Drug Metab."},{"key":"10.2133\/dmpk.23.328_bb0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/j.1552-4604.1996.tb04251.x","article-title":"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents","volume":"36","author":"von Moltke","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.23.328_bb0030","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0090-9556(24)15255-5","article-title":"Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole","volume":"27","author":"Gibbs","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0035","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1124\/dmd.30.12.1441","article-title":"Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors","volume":"30","author":"Tran","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0040","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1016\/0006-2952(81)90611-0","article-title":"Prediction of drug-drug interaction from in vitro plasma protein binding and metabolism. A study of tolbutamide-sulfonamide interaction in rats","volume":"30","author":"Sugita","year":"1981","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.23.328_bb0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0090-9556(25)07299-X","article-title":"Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships","volume":"24","author":"Ervine","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0050","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/j.1552-4604.1994.tb04735.x","article-title":"In vitro prediction of the terfenadineketoconazole pharmacokinetic interaction","volume":"34","author":"von Moltke","year":"1994","journal-title":"J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.23.328_bb0055","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","article-title":"Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants","volume":"62","author":"Tran","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.23.328_bb0060","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0009-9236(98)90041-8","article-title":"Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir","volume":"63","author":"Hsu","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.23.328_bb0065","first-page":"318","article-title":"Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats","volume":"26","author":"Takedomi","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0070","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1211\/0022357011775974","article-title":"In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation","volume":"53","author":"Takedomi","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"10.2133\/dmpk.23.328_bb0075","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0022-3565(24)35397-2","article-title":"Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver","volume":"292","author":"Yamano","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.23.328_bb0080","first-page":"443","article-title":"Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo\/in vitro absorption, distribution, and metabolism data","volume":"29","author":"Yamano","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-2797(99)00088-5","article-title":"Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential","volume":"121","author":"Li","year":"1999","journal-title":"Chem. Biol. Interact."},{"key":"10.2133\/dmpk.23.328_bb0090","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0090-9556(24)11800-4","article-title":"A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum","volume":"28","author":"Shibata","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0095","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1124\/dmd.30.8.892","article-title":"Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method","volume":"30","author":"Shibata","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0100","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.1993.03500120051025","article-title":"Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences","volume":"269","author":"Honig","year":"1993","journal-title":"JAMA"},{"key":"10.2133\/dmpk.23.328_bb0105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0021-9673(96)00702-9","article-title":"Determination of an in vivo metabolite of a human immunodeficiency virus protease-inhibitor in human plasma by high-performance liquid chromatography with tandem mass spectrometry","volume":"762","author":"Woolf","year":"1997","journal-title":"J. Chromatogr. A"},{"key":"10.2133\/dmpk.23.328_bb0110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00558224","article-title":"Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine","volume":"37","author":"Br\u00f8sen","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.23.328_bb0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2125.1997.00539.x","article-title":"Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects","volume":"43","author":"Spina","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.23.328_bb0120","first-page":"1185","article-title":"Pharmacokinetics and biotransformation studies of terfenadine in man","volume":"32","author":"Garteiz","year":"1982","journal-title":"Arzneimittelforschung"},{"key":"10.2133\/dmpk.23.328_bb0125","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.42.5.1308","article-title":"Single-dose pharmacokinetics of indinavir and the effect of food","volume":"42","author":"Yeh","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.2133\/dmpk.23.328_bb0130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/clpt.1988.66","article-title":"Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers","volume":"43","author":"Ciraulo","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.23.328_bb0135","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1128\/AAC.21.1.151","article-title":"Disposition of ketoconazole, an oral antifungal, in humans","volume":"21","author":"Brass","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.2133\/dmpk.23.328_bb0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev.pharmtox.38.1.461","article-title":"Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport","volume":"38","author":"Ito","year":"1998","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.2133\/dmpk.23.328_bb0145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF01062532","article-title":"Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies","volume":"7","author":"Guentert","year":"1979","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.2133\/dmpk.23.328_bb0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/bdd.2510020211","article-title":"Bioavailability of terfenadine in man","volume":"2","author":"Okerholm","year":"1981","journal-title":"Biopharm. Drug Dispos."},{"key":"10.2133\/dmpk.23.328_bb0155","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0090-9556(25)08479-X","article-title":"Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans","volume":"24","author":"Balani","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0160","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/js9802392","article-title":"Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis","volume":"88","author":"Yeh","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.2133\/dmpk.23.328_bb0165","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.2133\/dmpk.23.328_bb0170","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0090-9556(25)08414-4","article-title":"Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor","volume":"24","author":"Lin","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0175","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.2042-7158.1986.tb04540.x","article-title":"Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model","volume":"38","author":"Roberts","year":"1986","journal-title":"J. Pharm. Pharmacol."},{"key":"10.2133\/dmpk.23.328_bb0185","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0090-9556(25)07393-3","article-title":"Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation","volume":"21","author":"Yun","year":"1993","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0190","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.30.3.314","article-title":"Inhibition of cytochromes P450 by antifungal imidazole derivatives","volume":"30","author":"Zhang","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.2133\/dmpk.23.328_bb0200","first-page":"47","article-title":"Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general","volume":"2","author":"Boxenbaum","year":"1999","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.2133\/dmpk.23.328_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.25.1.1","article-title":"Influence of food on the pharmacokinetics of ketoconazole","volume":"25","author":"Daneshmend","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.2133\/dmpk.23.328_bb0210","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0090-9556(25)07348-9","article-title":"Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor","volume":"24","author":"Chiba","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.23.328_bb0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0169-409X(97)00044-6","article-title":"Human immunodeficiency virus protease inhibitors From drug design to clinical studies","volume":"27","author":"Lin","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.2133\/dmpk.23.328_bb0220","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/clpt.1984.239","article-title":"Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes","volume":"36","author":"Spina","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.23.328_bb0225","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/0006-2952(85)90533-7","article-title":"Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes","volume":"34","author":"von Bahr","year":"1985","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.23.328_bb0230","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1021\/js980197h","article-title":"Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo","volume":"87","author":"von Moltke","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.2133\/dmpk.23.328_bb0235","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/clpt.1988.76","article-title":"Inhibition of desipramine 2-hydroxylation by quinidine and quinine","volume":"43","author":"Steiner","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.23.328_bb0240","first-page":"201","article-title":"Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators","volume":"7","author":"Spina","year":"1989","journal-title":"Psychopharmacol. Ser."}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S134743671530207X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S134743671530207X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T14:05:49Z","timestamp":1738505149000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S134743671530207X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"alternative-id":["S134743671530207X"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.23.328","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}